Webinar Date/Time: Tue, Aug 15, 2023 11:00 AM EDT
Tackle complex characterization challenges for protein therapeutics with novel workflows. Learn about the link between AGE formation and color change in final drug products and how to develop assays for rapid monitoring and tracking of these PTMs.
Register Free: https://www.biopharminternational.com/bp_w/protein-quality-attribute
Event Overview:
Because a product quality attribute (PQA) may impact efficacy and safety, the color of a protein therapeutic under process development, and any changes to that color require close monitoring. Establishing multi-attribute methodology (MAM) to track the cause of color change facilitates efficiency in this monitoring by enabling rapid hot spot analysis for the continued development of the drug. This webinar discusses the use of a LC-MS workflow for detailed peptide mapping of PTMs to:
Key Learning Objectives:
Who Should Attend:
Speaker:
Andrew D. Mahan, PhD
Associate Director
Mass Spec Group Leader
Cell Engineering and Analytical Sciences
Janssen Research
Dr Andrew D. Mahan is enthusiastic and passionate about mass spectrometry and its role in bringing new medicines to patients. His mission focuses on the continuous improvement of mass spectrometry and in the flawless execution of analytical methods to support the organizations and teams he is a part of. Dr Andrew D. Mahan received his PhD in analytical chemistry from Drexel University and is currently the Associate Director and Mass Spec Group Leader of Cell Engineering and Analytical Sciences at Janssen Research in Spring House, PA, USA. There, he is focused on the analytical support of the cell line development group, applying mass spectrometry to solve problems and understand protein
expression.
Register Free: https://www.biopharminternational.com/bp_w/protein-quality-attribute
Texas' MD Anderson Cancer Center Creates New Cell Therapy Institute
November 11th 2024With the launch of the Institute for Cell Therapy Discovery and Innovation, the MD Anderson Cancer Center will bring together expertise in developing cell therapies for cancer, autoimmune diseases, and infections.